Edition:
United Kingdom

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

8.50USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$8.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,547
52-wk High
$9.80
52-wk Low
$5.00

Chart for

About

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications... (more)

Overall

Beta: 0.21
Market Cap(Mil.): $225.49
Shares Outstanding(Mil.): 27.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Kindred Biosciences Inc Files For Mixed Shelf Of Up To $150 Million

* KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​ Source text - (http://bit.ly/2risHPv) Further company coverage:

18 Jan 2018

BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz

* KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™

21 Dec 2017

BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral

* KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES

04 Dec 2017

BRIEF-Kindred Biosciences posts Q3 loss of $0.29 per share

* Kindred biosciences announces third quarter 2017 financial results

07 Nov 2017

Earnings vs. Estimates